Page 55 - IFM_201404 calość 300 dpi

Inżynier i Fizyk Medyczny 4/2014 vol. 3 213
kardiologia / cardiology artykuł naukowy / scientific paper
23. C. Correa, H. Litt, W. Hwang et al.: Coronary artery findings after
left – sided compared with right sided radiation treatment for early
stage breast cancer, J Clin Oncol, 25, 2007, 3031-3037.
24. J. Cuzick, H. Stewart, L. Rutqvist at al.: Cause-Specific Mortality
in Long-Term Survivors of Breast Cancer Who Participated in Trials
of Radiotherapy, J Clin Oncol, 12, 1994, 447-453.
25. QUANTEC Summary: Approximate Dose/Volume/Outcome Data
for Several Organs Following Conventional Fractionation, I. J. Ra-
diation Oncology Biology Physics, 76(3), 2010.
26. S. Lipshultz, S. Colan, R. Gerber at al.: Late cardiac effects of
doxorubicin therapy of acute lymphoblastic leukemia in childhood,
N. Engl. J. Med., 324, 1991, 808-815.
27. K. Shan, A. Licoff, J. Young: Anthracycline-induced cardiotoxicity,
Ann. Inter. Med., 125, 1996, 47-58.
28. O. Heuquet, Q. Le, I. Moullet at al.: Subclinical late cardiomyopa-
thy after doxorubicin therapy for lymphoma in adults, J. Clin. On-
col., 22, 2004, 1864-1871.
29. P. Horan, M. McMullin, P. McKeown: Anthracycline cardiotoxicity ,
Eur. Heart J., 27, 2006, 1137-1138.
30. S. Badurek: Odległe powikłania kardiologiczne terapii onkologicz-
nej, Kardiologia Polska, 61, 2004, 296.
31. S. Aggarwal, M. Pettersen, K. Bhambhani et al.: B-type natriu-
retic peptide as a marker for cardiac dysfunction in anthracycline
treated children, Pediatr Blood Cancer, 49, 2007, 812-816.
32. H. Auner, C. Tinchon, W. Linkesch et al.: Prolonged monitoring
of troponin T for the detection of anthacycline cardiotoxicity in
adults with hematological malignancies, Ann Hematol., 82, 2003,
218-222.
33. F. Dodos, T. Halbsguth, E. Erdmann et al.: Usefulness of myocar-
dial performance index and biochemical markers for early detec-
tion of antharcycline-induced cardiotoxicity in adults. Clin Res
Cardiol., 97, 2008, 318-326.
34. J. Bryant, J. Picot, L. Baxter et al.: Use of cardiac markers to as-
sess the toxic effects of antharcyclines given to children with can-
cer: A systematic review, Eur J Cancer., 43, 2007, 1959-1966.
35. L. Wojnowski, B. Kulle, M. Schirmer, et al.: NAD (P) H oxidase and
multidrug resistance protein genetic polymorphisms are associated
with doxorubicin-induced cardiotoxicity, Circulation, 112, 2005,
3754-3762.
36. B. Jensen, T. Skovsgaard, S. Nielsen: Functional monitoring of
anthracycline cardiotoxicity: a prospective, blinded, long term
observational study of outcome in 120 patients, Ann Oncol., 13,
2002, 699-709.
37. R. Altena, P. Perik, D. van Veldhuisen et al.: Cardiovascular toxici-
ty caused by cancer treatment: strategies for early detection, Lan-
cet Oncol., 10, 2009, 391-399.
38. L. Smith, V. Cornelius, C. Plummer et al.: Cardiotoxicity of anthra-
cycline agents for the treatment of cancer: systematic review and
meta – analysis of randomized controlled trials, BMC Cancer, 10,
2010, 337-350.
39. P. Morris, C. Hudis: Trastuzumab – related cardiotoxicity following
anthracycline – based adjuvant chemotherapy: How worried sho-
uld we be?, J Clin Oncol., 29, 2010, 3407-3410.
40. M. Levine: Trastuzumab cardiac side effects: only time will tell,
J Clin Oncol., 23, 2005, 7775-7776.
41. C. Tocchetti, G. Ragone, C. Capola at al.: Detection, monitoring,
and management of trastuzumab-induced left ventricular dysfunc-
tion: an actual challenge, European Journal of Heart Failure,
14(2), 130-137.
42. K. Fox: The evaluation of left ventricular function for patients be-
ing considered for, or receiving Trastuzumab (Herceptin) therapy,
Br J Cancer, 95, 2006, 1454.
43. E. Romond, E. Perez, J. Bryant at al.: Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer, N Engl
J Med., 353(16), 2005, 1673-1684.
44. M. Halyard, T. Pisansky, A. Dueck et al.: Radiotherapy and ad-
juwant trastuzumab in operable breast cancer: tolerability and
adverse event data from the NCCTG phase III trail N9831, J Clin
Oncol., 27, 2009, 2638-2644.
reklama